Global Insulin Delivery Devices Market Outlook, 2031
The Global Insulin Delivery Devices Market is segmented By Product Types (Insulin Pens, Insulin Pump, Insulin Syringes, Other Insulin Delivery Devices); By Disease Types (Type 1, Type 2); By End User (Home Care Setting, Hospitals & Clinics, Other End Users).
- Bonafide Research
- 22-01-2026
- Pages : 190
- Figures : 36
- Tables : 86
- Region : Global
- Category : Lifescience & Healthcare
- Medical Devices
The global insulin delivery devices market was valued at over USD 34.07 Billion in 2025 and is projected to reach USD 51.73 Billion by 2031 (CAGR 7.39%).
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 34.07 Billion
- Market Size (2031) USD 51.73 Billion
- CAGR (2026-2031) 7.39%
- Largest MarketNorth America
- Fastest Market Asia-Pacific
- Format
Featured Companies
- 1. Medline Industries, LP
- 2. Beckton Dickinson
- 3. Sanofi S.A.
- 4. Medtronic plc
- 5. Microport
- 6. B. Braun Melsungen AG
- 7. Terumo Corporation
- 8. Novo Nordisk A/S
- 9. Eli Lilly and Company
- More...
Insulin Delivery Devices Market Analysis
Insulin delivery devices are medical devices designed to administer insulin, a hormone used in the management of diabetes, into the body. These devices are primarily used by individuals with diabetes who require insulin therapy to regulate their blood sugar levels. Insulin pens, pumps, pen needles, and syringes are the most widely used delivery devices. The insulin delivery devices market is experiencing steady growth, primarily due to the increasing number of individuals diagnosed with diabetes. The insulin delivery devices market can be categorized into several types like insulin pens, insulin pumps, insulin syringes, insulin pen needles, and other insulin delivery devices. Within the category of insulin pens, there are two main types which are reusable insulin pens and disposable insulin pens. As of 2024, reusable insulin pens held the largest market share. Reusable insulin pens feature a delivery chamber designed to hold prefilled insulin cartridges. These devices are more cost-effective than disposable insulin pens, leading to their increasing popularity for insulin delivery. They provide significant advantages in terms of affordability, sustainability, and user-friendliness. Additionally, reusable pens offer environmental benefits. The wearable healthcare devices market is segmented into general health & fitness, remote patient monitoring, and home healthcare. General health & fitness wearables lead in demand due to their widespread use for preventive health, wellness tracking, and lifestyle management, followed by remote patient monitoring and home healthcare, which are increasingly adopted for chronic disease management and telehealth applications. According to the research report "Global Insulin Delivery Devices Market Outlook, 2031," published by Bonafide Research, the Global Insulin Delivery Devices market was valued at more than USD 34.07 Billion in 2025, and expected to reach a market size of more than USD 51.73 Billion by 2031 with the CAGR of 7.39% from 2026-2031. Technological advancements in diabetes management have significantly transformed insulin delivery methods, evolving from traditional injections to more advanced, minimally invasive techniques. Initially, insulin administration faced challenges in maintaining consistent blood glucose levels. However, the advent of insulin pens facilitated easier self-administration, reducing discomfort. The development of insulin pumps allowed for continuous insulin infusion, enhancing glucose control. A pivotal advancement was the introduction of Continuous Glucose Monitoring (CGM) devices, providing real-time glucose data, essential for informed decision-making. This set the stage for Artificial Pancreas Systems (APS), which integrate CGM data with insulin pumps for automated delivery, closely mimicking natural pancreatic function. Bionic technology, blending biological and artificial processes, has been instrumental in advancing insulin delivery. It underpins devices such as APS, utilizing algorithms, sensors, and automated pumps for precise blood sugar regulation, minimizing manual intervention. These innovations offer tailored, user-friendly solutions, notably improving patient outcomes. Modern insulin pumps, equipped with CGM integration, predictive algorithms, and smartphone connectivity, exemplify significant progress in device functionality, offering accurate and adaptable insulin management. These features not only mitigate risks associated with blood glucose extremes but also empower users with finer control over their insulin dosing, responding dynamically to glucose level changes.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamic
Market Drivers • Rising Global Prevalence of Diabetes: A primary driver for the global insulin delivery devices market is the rapidly increasing incidence of diabetes worldwide, particularly Type 1 and Type 2 diabetes. With shifting lifestyles, urbanization, aging populations, and sedentary behavior leading to more diagnoses year after year, a growing pool of patients requires regular insulin therapy for glycemic control. This expanding diabetic population creates a sustained and rising demand for both traditional and advanced insulin delivery systems such as pens, pumps, and automated devices because effective insulin administration is critical to managing the disease and preventing complications. • Technological Advancements and Innovation: Another key growth driver is the rapid pace of innovation in insulin delivery technologies, which has broadened the market’s appeal beyond traditional syringes. Manufacturers are investing heavily in smart insulin pens, continuous glucose monitor (CGM)-integrated pumps, wearable patch systems, and closed-loop artificial pancreas solutions that offer real-time glucose tracking, automated dose adjustments, connectivity with mobile applications, and personalized insulin administration. These technological improvements make devices more accurate, convenient, and responsive to individual needs, enhancing patient satisfaction and adherence. Market Challenges • Affordability Constraints: A significant challenge facing the global insulin delivery devices market is the high cost of advanced devices and associated consumables. Technologies such as insulin pumps, CGM-integrated systems, and smart pens deliver superior functionality but often come with premium price tags that many patients find prohibitive especially in low- and middle-income regions. High device costs, combined with ongoing maintenance and accessory expenses, limit accessibility for large populations without comprehensive insurance coverage or government reimbursement. • Technical Integration Issues: As insulin delivery devices become more connected and digitally enabled, they face technical and cybersecurity challenges that could hinder trust and adoption. Connected devices often transmit sensitive health data via Bluetooth or Wi-Fi to companion apps and cloud platforms, raising concerns about data security and privacy. Healthcare providers and patients alike worry about potential breaches that could compromise personal health information. Beyond cybersecurity, integrating delivery devices into broader digital ecosystems such as interoperable platforms with continuous glucose monitoring systems or remote management tools introduces complexity. Market Trends • Integration of Digital and Smart Technologies: A major trend shaping the insulin delivery devices market is the integration of digital technologies into device design and functionality. Smart insulin pens and pumps are increasingly equipped with Bluetooth connectivity, mobile app compatibility, and real-time data logging that enable patients to monitor glucose trends, track doses, and share information with healthcare providers. Some systems are advancing toward closed-loop automation, combining insulin Pumps with continuous glucose monitoring and AI algorithms to deliver insulin dynamically based on real-time glucose readings. • Personalized Healthcare Solutions: Another evolving trend is the rise of wearable insulin delivery solutions and personalized treatment approaches. Wearable devices such as tubeless patch pumps and hybrid automated delivery systems are becoming more popular due to their convenience, minimally invasive design, and ability to support lifestyle flexibility for users. At the same time, there is a broader industry move toward personalized healthcare, where devices and dosing strategies are tailored to individual physiological needs, behaviors, and daily routines.
Insulin Delivery Devices Segmentation
| By product Types | Insulin Pens | |
| Insulin Pump | ||
| Insulin Syringes | ||
| Others Insulin Delivery Devices | ||
| By Disease Types | Type 1 | |
| Type 2 | ||
| By End User | Home care setting | |
| Hospitals & clinics | ||
| Others End users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| MEA | United Arab Emirates | |
| Saudi Arabia | ||
| South Africa | ||
Insulin pens are the largest product type in the global insulin delivery devices market because they offer the best balance of convenience accuracy affordability and patient acceptance compared to other insulin delivery options. Unlike traditional syringes insulin pens are prefilled or refillable devices that allow patients to administer insulin quickly and discreetly with minimal preparation. This simplicity is especially important for the growing number of elderly patients and newly diagnosed individuals who may find complex delivery systems intimidating or difficult to manage. Insulin pens provide precise and consistent dosing through dial based mechanisms which reduces dosing errors and improves glycemic control compared to manual syringe measurement. This accuracy builds confidence among patients and healthcare providers and encourages long term adherence to insulin therapy. Another major reason for their widespread adoption is portability and convenience. Insulin pens are compact lightweight and easy to carry making them suitable for use at home work or during travel without drawing attention. This discretion reduces social stigma associated with insulin injections and significantly improves patient comfort and willingness to comply with prescribed treatment regimens. From a clinical perspective insulin pens also reduce injection pain due to the use of finer and shorter needles which improves the overall user experience and leads to better therapy continuation rates. Cost is another critical factor supporting the dominance of insulin pens. While more advanced technologies such as insulin pumps and automated delivery systems offer additional features they are expensive and often inaccessible to patients in low and middle income regions. Insulin pens on the other hand are considerably more affordable and are widely covered by insurance and government reimbursement programs in many countries. Type 2 diabetes holds the largest share in the global insulin delivery devices market because it affects a vastly larger population and increasingly requires long term insulin therapy as the disease progresses. As urbanization and sedentary lifestyles continue to rise across both developed and developing regions the number of people diagnosed with type 2 diabetes has increased dramatically creating a very large patient base that drives demand for insulin delivery devices. Although many type 2 patients initially manage their condition with oral antidiabetic drugs and lifestyle modifications disease progression frequently results in declining beta cell function which reduces the body ability to produce sufficient insulin. As a result a significant proportion of type 2 patients eventually require insulin therapy either as basal insulin supplementation or in combination with oral medications which directly expands the need for insulin pens syringes and other delivery systems. Another important factor is the long duration of treatment. Type 2 diabetes is a chronic lifelong condition and once insulin therapy is initiated it is often continued for many years which leads to sustained and recurring demand for insulin delivery devices. This long term usage pattern significantly increases market volume compared to type 1 diabetes which although insulin dependent from diagnosis represents a much smaller patient population. The growing aging population also plays a crucial role since type 2 diabetes prevalence rises sharply with age and older patients are more likely to experience disease progression requiring insulin. From healthcare system perspective insulin delivery devices for type 2 diabetes are widely prescribed because they offer flexible dosing options that can be adjusted to match disease severity lifestyle and comorbid conditions. Home care settings dominate the global insulin delivery devices market because diabetes requires frequent lifelong insulin administration that patients can most conveniently and consistently manage at home. Insulin delivery devices such as pens syringes and pumps are specifically designed for self-administration which naturally aligns with home care use. Advances in device design have made insulin delivery simpler safer and more intuitive enabling patients and caregivers to perform injections accurately without continuous medical supervision. This ease of use has significantly increased confidence in home based insulin management among both patients and healthcare providers. Another important factor driving the dominance of home care is cost efficiency. Hospital stays and frequent clinic visits significantly increase healthcare expenses for patients insurers and healthcare systems. Home care reduces these costs by minimizing the need for professional administration and inpatient care while still allowing effective disease management. As healthcare systems worldwide shift toward value based care and cost containment home based treatment models are strongly encouraged which directly supports the widespread use of insulin delivery devices in home settings. Patient preference also plays a major role. Many individuals with diabetes prefer the privacy and flexibility of administering insulin at home rather than in clinical environments. Home care reduces treatment related stress improves adherence and enhances quality of life especially for elderly patients and those with mobility limitations. The growing elderly population combined with rising diabetes prevalence further strengthens the demand for home based insulin delivery. Technological advancements have also reinforced this trend.
to Download this information in a PDF
Insulin Delivery Devices Market Regional Insights
North America is the largest market for insulin delivery devices because it has a high diabetes prevalence combined with advanced healthcare infrastructure strong reimbursement systems and rapid adoption of innovative medical technologies. One of the most significant contributors is the high prevalence of diabetes particularly type 2 diabetes driven by lifestyle factors such as obesity sedentary behavior aging populations and dietary patterns. The United States and Canada together represent a very large patient pool requiring long term insulin therapy which directly increases demand for insulin delivery devices on a sustained basis. In addition North America has a well-developed healthcare infrastructure with widespread access to hospitals clinics pharmacies and home care services which ensures that insulin delivery devices are readily available and consistently used across all stages of diabetes management. Strong reimbursement and insurance coverage play a critical role in supporting market dominance. Many public and private insurance plans in the region cover insulin delivery devices including insulin pens pumps and related consumables which significantly reduces out of pocket costs for patients and encourages the use of advanced delivery systems. This financial support makes it easier for patients to transition from traditional syringes to more convenient and technologically advanced devices. Another major factor is the high level of awareness among patients and healthcare professionals regarding diabetes management and the importance of tight glycemic control. Physicians in North America are more likely to prescribe modern insulin delivery devices early in the treatment pathway to improve adherence reduce complications and enhance patient quality of life. Technological leadership further strengthens the region market position.
to Download this information in a PDF
Key Development
• July 2025: Medtronic’s MiniMed 780G system received expanded CE mark approval in Europe for use in children aged two years and older, pregnant women, and Type 2 diabetes patients, backed by improved HbA1c and glucose control data. • June 2025: Insulet presented new data on its Omnipod 5 AID system at the American Diabetes Association’s Scientific Sessions, noting that over 30% of new users in the first quarter were patients with Type 2 diabetes, following expanded FDA approval and growing provider interest. • June 2025: Tandem Diabetes Care partnered with Abbott to integrate its insulin delivery systems with Abbott’s upcoming dual glucose-ketone sensor, aiming to enhance real-time monitoring and prevent diabetic ketoacidosis through earlier ketone detection. • January 2025: Novo Nordisk A S launched Awiqli insulin icodec injection in Japan in a prefilled FlexTouch pen offering a once weekly basal insulin option for adults with diabetes.This launch represents a major advancement in insulin therapy by reducing injection frequency and improving treatment convenience and adherence for patients. • December 2024 : Novo Nordisk successfully completed the acquisition of three manufacturing facilities from Novo Holdings A/S. This transaction follows Novo Holdings’ finalization of its acquisition of Catalent, Inc. (Catalent), a leading global contract development and manufacturing organization (CDMO). The integration of these manufacturing sites aligns with Novo Nordisk’s strategic objective of expanding access to its current and future treatments for individuals living with diabetes and obesity. • November 2024 : Medtronic received USFDA approval for the InPen System, which is a home-use reusable pen for single-patient used by people with diabetes under the supervision of an adult caregiver, or by a patient aged 7 and older for the self-injection of a desired dose of insulin. • August 2024 : Embecta Corp. announced that it has received 510(k) clearance from the USFDA for its proprietary disposable insulin delivery system. This system features a tubeless patch pump design equipped with a 300-unit insulin reservoir. • August 2024: Abbott and Medtronic announced a unique global partnership to work together on an integrated continuous glucose monitoring (CGM) system that will connect to Medtronic's automated insulin delivery (AID) and smart insulin pen systems. The system will be built on Abbott's most cutting-edge, industry-leading FreeStyle Libre technology. • August 2024: the U.S. Food and Drug Administration (FDA) approved the SimpleraTM continuous glucose monitor (CGM), the company's first disposable, all-in-one CGM that is half the size of earlier Medtronic CGMs. Medtronic plc is a global pioneer in healthcare technology. • August 2024: as the first and only AID system FDA-approved for the management of both type 1 and type 2 diabetes, Insulet Corporation announced that its revolutionary Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now recommended for use by individuals with type 2 diabetes (those aged 18 and older) in the United States.
Companies Mentioned
- Medline Industries, LP
- Beckton Dickinson
- Sanofi S.A.
- Medtronic plc
- Microport
- B. Braun Melsungen AG
- Terumo Corporation
- Novo Nordisk A/S
- Eli Lilly and Company
- Insulet Corporation
- Tandem Diabetes Care
- Wockhardt Ltd.
- SOOIL Development Co., Ltd
- MannKind Corporation
- Owen Mumford Ltd
- Debiotech SA
- Ypsomed AG
- Hindustan Syringes & Medical Devices Ltd
- Roche Holding AG
- Haselmeier GmbH
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Global Insulin Delivery Devices Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Region
- 6.3. Market Size and Forecast, By Geography
- 6.4. Market Size and Forecast, By Product Types
- 6.5. Market Size and Forecast, By Disease Types
- 6.6. Market Size and Forecast, By End User
- 7. North America Insulin Delivery Devices Market Outlook
- 7.1. Market Size By Value
- 7.2. Market Share By Country
- 7.3. Market Size and Forecast, By Product Types
- 7.4. Market Size and Forecast, By Disease Types
- 7.5. Market Size and Forecast, By End User
- 7.6. United States Insulin Delivery Devices Market Outlook
- 7.6.1. Market Size by Value
- 7.6.2. Market Size and Forecast By Product Types
- 7.6.3. Market Size and Forecast By Disease Types
- 7.6.4. Market Size and Forecast By End User
- 7.7. Canada Insulin Delivery Devices Market Outlook
- 7.7.1. Market Size by Value
- 7.7.2. Market Size and Forecast By Product Types
- 7.7.3. Market Size and Forecast By Disease Types
- 7.7.4. Market Size and Forecast By End User
- 7.8. Mexico Insulin Delivery Devices Market Outlook
- 7.8.1. Market Size by Value
- 7.8.2. Market Size and Forecast By Product Types
- 7.8.3. Market Size and Forecast By Disease Types
- 7.8.4. Market Size and Forecast By End User
- 8. Europe Insulin Delivery Devices Market Outlook
- 8.1. Market Size By Value
- 8.2. Market Share By Country
- 8.3. Market Size and Forecast, By Product Types
- 8.4. Market Size and Forecast, By Disease Types
- 8.5. Market Size and Forecast, By End User
- 8.6. Germany Insulin Delivery Devices Market Outlook
- 8.6.1. Market Size by Value
- 8.6.2. Market Size and Forecast By Product Types
- 8.6.3. Market Size and Forecast By Disease Types
- 8.6.4. Market Size and Forecast By End User
- 8.7. United Kingdom (UK) Insulin Delivery Devices Market Outlook
- 8.7.1. Market Size by Value
- 8.7.2. Market Size and Forecast By Product Types
- 8.7.3. Market Size and Forecast By Disease Types
- 8.7.4. Market Size and Forecast By End User
- 8.8. France Insulin Delivery Devices Market Outlook
- 8.8.1. Market Size by Value
- 8.8.2. Market Size and Forecast By Product Types
- 8.8.3. Market Size and Forecast By Disease Types
- 8.8.4. Market Size and Forecast By End User
- 8.9. Italy Insulin Delivery Devices Market Outlook
- 8.9.1. Market Size by Value
- 8.9.2. Market Size and Forecast By Product Types
- 8.9.3. Market Size and Forecast By Disease Types
- 8.9.4. Market Size and Forecast By End User
- 8.10. Spain Insulin Delivery Devices Market Outlook
- 8.10.1. Market Size by Value
- 8.10.2. Market Size and Forecast By Product Types
- 8.10.3. Market Size and Forecast By Disease Types
- 8.10.4. Market Size and Forecast By End User
- 8.11. Russia Insulin Delivery Devices Market Outlook
- 8.11.1. Market Size by Value
- 8.11.2. Market Size and Forecast By Product Types
- 8.11.3. Market Size and Forecast By Disease Types
- 8.11.4. Market Size and Forecast By End User
- 9. Asia-Pacific Insulin Delivery Devices Market Outlook
- 9.1. Market Size By Value
- 9.2. Market Share By Country
- 9.3. Market Size and Forecast, By Product Types
- 9.4. Market Size and Forecast, By Disease Types
- 9.5. Market Size and Forecast, By End User
- 9.6. China Insulin Delivery Devices Market Outlook
- 9.6.1. Market Size by Value
- 9.6.2. Market Size and Forecast By Product Types
- 9.6.3. Market Size and Forecast By Disease Types
- 9.6.4. Market Size and Forecast By End User
- 9.7. Japan Insulin Delivery Devices Market Outlook
- 9.7.1. Market Size by Value
- 9.7.2. Market Size and Forecast By Product Types
- 9.7.3. Market Size and Forecast By Disease Types
- 9.7.4. Market Size and Forecast By End User
- 9.8. India Insulin Delivery Devices Market Outlook
- 9.8.1. Market Size by Value
- 9.8.2. Market Size and Forecast By Product Types
- 9.8.3. Market Size and Forecast By Disease Types
- 9.8.4. Market Size and Forecast By End User
- 9.9. South Korea Insulin Delivery Devices Market Outlook
- 9.9.1. Market Size by Value
- 9.9.2. Market Size and Forecast By Product Types
- 9.9.3. Market Size and Forecast By Disease Types
- 9.9.4. Market Size and Forecast By End User
- 9.10. Australia Insulin Delivery Devices Market Outlook
- 9.10.1. Market Size by Value
- 9.10.2. Market Size and Forecast By Product Types
- 9.10.3. Market Size and Forecast By Disease Types
- 9.10.4. Market Size and Forecast By End User
- 10. South America Insulin Delivery Devices Market Outlook
- 10.1. Market Size By Value
- 10.2. Market Share By Country
- 10.3. Market Size and Forecast, By Product Types
- 10.4. Market Size and Forecast, By Disease Types
- 10.5. Market Size and Forecast, By End User
- 10.6. Brazil Insulin Delivery Devices Market Outlook
- 10.6.1. Market Size by Value
- 10.6.2. Market Size and Forecast By Product Types
- 10.6.3. Market Size and Forecast By Disease Types
- 10.6.4. Market Size and Forecast By End User
- 10.7. Argentina Insulin Delivery Devices Market Outlook
- 10.7.1. Market Size by Value
- 10.7.2. Market Size and Forecast By Product Types
- 10.7.3. Market Size and Forecast By Disease Types
- 10.7.4. Market Size and Forecast By End User
- 10.8. Colombia Insulin Delivery Devices Market Outlook
- 10.8.1. Market Size by Value
- 10.8.2. Market Size and Forecast By Product Types
- 10.8.3. Market Size and Forecast By Disease Types
- 10.8.4. Market Size and Forecast By End User
- 11. Middle East & Africa Insulin Delivery Devices Market Outlook
- 11.1. Market Size By Value
- 11.2. Market Share By Country
- 11.3. Market Size and Forecast, By Product Types
- 11.4. Market Size and Forecast, By Disease Types
- 11.5. Market Size and Forecast, By End User
- 11.6. United Arab Emirates (UAE) Insulin Delivery Devices Market Outlook
- 11.6.1. Market Size by Value
- 11.6.2. Market Size and Forecast By Product Types
- 11.6.3. Market Size and Forecast By Disease Types
- 11.6.4. Market Size and Forecast By End User
- 11.7. Saudi Arabia Insulin Delivery Devices Market Outlook
- 11.7.1. Market Size by Value
- 11.7.2. Market Size and Forecast By Product Types
- 11.7.3. Market Size and Forecast By Disease Types
- 11.7.4. Market Size and Forecast By End User
- 11.8. South Africa Insulin Delivery Devices Market Outlook
- 11.8.1. Market Size by Value
- 11.8.2. Market Size and Forecast By Product Types
- 11.8.3. Market Size and Forecast By Disease Types
- 11.8.4. Market Size and Forecast By End User
- 12. Competitive Landscape
- 12.1. Competitive Dashboard
- 12.2. Business Strategies Adopted by Key Players
- 12.3. Key Players Market Share Insights and Analysis, 2025
- 12.4. Key Players Market Positioning Matrix
- 12.5. Porter's Five Forces
- 12.6. Company Profile
- 12.6.1. Novo Nordisk A/S
- 12.6.1.1. Company Snapshot
- 12.6.1.2. Company Overview
- 12.6.1.3. Financial Highlights
- 12.6.1.4. Geographic Insights
- 12.6.1.5. Business Segment & Performance
- 12.6.1.6. Product Portfolio
- 12.6.1.7. Key Executives
- 12.6.1.8. Strategic Moves & Developments
- 12.6.2. Sanofi S.A.
- 12.6.3. Medtronic plc
- 12.6.4. Eli Lilly and Company
- 12.6.5. Becton, Dickinson and Company
- 12.6.6. B. Braun Melsungen SE
- 12.6.7. Terumo Corporation
- 12.6.8. Roche Holding AG
- 12.6.9. Insulet Corporation
- 12.6.10. Medline Inc.
- 12.6.11. Ypsomed Holding AG
- 12.6.12. Owen Mumford Ltd.
- 12.6.13. Hindustan Syringes & Medical Device Ltd.
- 12.6.14. MicroPort Inc.
- 12.6.15. Haselmeier GmbH
- 12.6.16. MannKind Corporation
- 12.6.17. Tandem Diabetes Care, Inc.
- 12.6.18. Debiotech S.A.
- 12.6.19. Wockhardt Ltd.
- 12.6.20. SOOIL Developments Co., Ltd.
- 13. Strategic Recommendations
- 14. Annexure
- 14.1. FAQ`s
- 14.2. Notes
- 14.3. Related Reports
- 15. Disclaimer
Table 2: Influencing Factors for Insulin Delivery Devices Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Insulin Delivery Devices Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Insulin Delivery Devices Market Size and Forecast, By Product Types (2020 to 2031F) (In USD Billion)
Table 8: Global Insulin Delivery Devices Market Size and Forecast, By Disease Types (2020 to 2031F) (In USD Billion)
Table 9: Global Insulin Delivery Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 10: North America Insulin Delivery Devices Market Size and Forecast, By Product Types (2020 to 2031F) (In USD Billion)
Table 11: North America Insulin Delivery Devices Market Size and Forecast, By Disease Types (2020 to 2031F) (In USD Billion)
Table 12: North America Insulin Delivery Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 13: United States Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 14: United States Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 15: United States Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 16: Canada Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 17: Canada Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 18: Canada Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 19: Mexico Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 20: Mexico Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 21: Mexico Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 22: Europe Insulin Delivery Devices Market Size and Forecast, By Product Types (2020 to 2031F) (In USD Billion)
Table 23: Europe Insulin Delivery Devices Market Size and Forecast, By Disease Types (2020 to 2031F) (In USD Billion)
Table 24: Europe Insulin Delivery Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 25: Germany Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 26: Germany Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 27: Germany Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 28: United Kingdom (UK) Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 29: United Kingdom (UK) Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 30: United Kingdom (UK) Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 31: France Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 32: France Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 33: France Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 34: Italy Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 35: Italy Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 36: Italy Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 37: Spain Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 38: Spain Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 39: Spain Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 40: Russia Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 41: Russia Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 42: Russia Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 43: Asia-Pacific Insulin Delivery Devices Market Size and Forecast, By Product Types (2020 to 2031F) (In USD Billion)
Table 44: Asia-Pacific Insulin Delivery Devices Market Size and Forecast, By Disease Types (2020 to 2031F) (In USD Billion)
Table 45: Asia-Pacific Insulin Delivery Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 46: China Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 47: China Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 48: China Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 49: Japan Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 50: Japan Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 51: Japan Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 52: India Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 53: India Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 54: India Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 55: South Korea Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 56: South Korea Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 57: South Korea Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 58: Australia Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 59: Australia Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 60: Australia Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 61: South America Insulin Delivery Devices Market Size and Forecast, By Product Types (2020 to 2031F) (In USD Billion)
Table 62: South America Insulin Delivery Devices Market Size and Forecast, By Disease Types (2020 to 2031F) (In USD Billion)
Table 63: South America Insulin Delivery Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 64: Brazil Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 65: Brazil Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 66: Brazil Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 67: Argentina Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 68: Argentina Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 69: Argentina Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 70: Colombia Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 71: Colombia Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 72: Colombia Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 73: Middle East & Africa Insulin Delivery Devices Market Size and Forecast, By Product Types (2020 to 2031F) (In USD Billion)
Table 74: Middle East & Africa Insulin Delivery Devices Market Size and Forecast, By Disease Types (2020 to 2031F) (In USD Billion)
Table 75: Middle East & Africa Insulin Delivery Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 76: United Arab Emirates (UAE) Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 77: United Arab Emirates (UAE) Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 78: United Arab Emirates (UAE) Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 79: Saudi Arabia Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 80: Saudi Arabia Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 81: Saudi Arabia Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 82: South Africa Insulin Delivery Devices Market Size and Forecast By Product Types (2020 to 2031F) (In USD Billion)
Table 83: South Africa Insulin Delivery Devices Market Size and Forecast By Disease Types (2020 to 2031F) (In USD Billion)
Table 84: South Africa Insulin Delivery Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 85: Competitive Dashboard of top 5 players, 2025
Table 86: Key Players Market Share Insights and Analysis for Insulin Delivery Devices Market 2025
Figure 2: Market attractiveness Index, By Region 2030
Figure 3: Market attractiveness Index, By Segment 2030
Figure 4: Global Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Insulin Delivery Devices Market Share By Region (2025)
Figure 6: North America Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Insulin Delivery Devices Market Share By Country (2025)
Figure 8: US Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Insulin Delivery Devices Market Share By Country (2025)
Figure 13: Germany Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Insulin Delivery Devices Market Share By Country (2025)
Figure 21: China Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: South Korea Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: Australia Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Insulin Delivery Devices Market Share By Country (2025)
Figure 28: Brazil Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Insulin Delivery Devices Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Insulin Delivery Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Insulin Delivery Devices Market
Insulin Delivery Devices Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (01 May, 2026)
- Notify To Team (01 May, 2026)
- Report updation (02 May, 2026)
- Report Quality Check (02 May, 2026)
- Report Dispatch (03 May, 2026)
- Hard Copy
Recently Viewed Products
Global Insulin Delivery Devices Market Outlook, 2031
We are friendly and approachable, give us a call.